Sichuan Kelun-Biotech Biopharmaceutical stock
Price history
−9.37% over the period1 year: from $439.60 (November 20, 2025) to $398.40 (November 20, 2026), −9.37%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $398.40 |
| October 30, 2026 | $424.80 |
| September 30, 2026 | $487.00 |
| August 31, 2026 | $497.20 |
| July 31, 2026 | $483.80 |
| June 30, 2026 | $436.20 |
| May 29, 2026 | $462.00 |
| April 30, 2026 | $469.40 |
| March 31, 2026 | $460.00 |
| February 27, 2026 | $387.40 |
| January 30, 2026 | $415.40 |
| December 31, 2025 | $393.40 |
| November 28, 2025 | $456.40 |
| November 20, 2025 | $439.60 |
At a glance
The company
Biopharmaceutical company developing novel drugs in oncology, immunology, metabolism and other therapeutic areas
Latest results
Quarter to June 30, 2026 · EPS ¥1.66
Next event
TickerLandia's take on Sichuan Kelun-Biotech Biopharmaceutical
- Pricier than similar companies: trailing 12-month P/E 553 vs 37 (+1,405%) in a group of 8.
- Strong point: Financial strength (55/100 in its group). Weak point: Earnings stability (13/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−29.17% from the 52-week high
Analysts · 21 analysts
Average target$617.60+55.02% vs. price
Buy 20 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Sichuan Kelun-Biotech Biopharmaceutical
Compared with similar companies: very high price and very low earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high92
How much it costs relative to what it produces.
Metric Value Position in group Price/book 15.7 92 Price/sales 48.3 89 Forward P/E 128.7 94 Profitabilitylow37
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 74.6% 45 Operating margin −0.2% 30 ROE 2.9% 29 ROA −0.0% 34 Net margin 7.2% 47 Earnings stabilityvery low13
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1,087.7% 15 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthlow29
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +2.90% 18 Average revenue growth (3 years) +36.79% 66 Earnings growth (year over year) −361.06% 4 Financial strengthaverage55
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −68.1 6 Debt/equitycounts in reverse: lower means more financial strength 0.02 83 Current ratio 6.34 76 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak39
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −9.37% 34 Relative strength (3 months) −14.29% 24 Distance from 200-day average −12.88% 40 Relative strength (6 months) +4.35% 58 Riskaverage57
How much the price swings.
Metric Value Position in group Volatility (60 days) 47.9% 68 Maximum drawdown (12 months) 28.8% 38 Beta (1 year) 0.96 64
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sichuan Kelun-Biotech Biopharmaceutical is pricier than similar companies
Sichuan Kelun-Biotech Biopharmaceutical's Forward P/E: 121.7, +284% against the median of a group of 11 similar companies (31.7).
Compared with 11 similar companies
| Metric | Sichuan Kelun-Biotech Biopharmaceutical | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 121.7 | High | |
| Operating margin | -0.2% | Low | |
| ROE | 2.9% | Low | |
| Debt/equity | 0.02 | Low | |
| Price/book | 14.8 | High |
Grey band: the middle half of the group; tick: the median; dot: Sichuan Kelun-Biotech Biopharmaceutical. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥978.34M
Latest quarter · Q2 2026
Net income
¥388.01M
Latest quarter · Q2 2026
Quarterly net margin
39.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $95.23B
- P/E
- 553.3
- EPS
- $0.72
- Volume
- 1.05M
- Daily trading
- €44.73M
- Dividend yield
- 0.00%
How Sichuan Kelun-Biotech Biopharmaceutical is changing
All resultsRevenue grew 36.8% a year on average over the last 3 years
Operating margin rose from −49.0% to −20.4%
Shares outstanding up 141.4% in 3 years
Returns
Sichuan Kelun-Biotech Biopharmaceutical returns
$1,000 invested in Sichuan Kelun-Biotech Biopharmaceutical 3 years ago, on November 20, 2023, would be worth $4,390 today: +339.01% in total, +63.72% per year. This is the price return only: dividends are excluded.
| Period | Sichuan Kelun-Biotech Biopharmaceutical | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −14.87% | −6.10% | $851 |
| 6 months | −8.83% | −12.63% | $912 |
| Year to date | +1.27% | −12.56% | $1,013 |
| 1 year | −9.37% | −13.26% | $906 |
| 3 years | +339.01% | +26.06% | $4,390 |
Over the last 6 months it has done better than 28% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Sichuan Kelun-Biotech Biopharmaceutical: technical analysis
Sichuan Kelun-Biotech Biopharmaceutical is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 31.0% below its all-time closing high ($577.50, October 8, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 34
- Between 30 and 70
- vs 200-session average
- −12.88%
Active signals
Death cross: the 50-session average has crossed below the 200-session average.
since November 19, 2026
Support and resistance
Price areas where Sichuan Kelun-Biotech Biopharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$453.95+13.94%4 touches, last on September 28, 2026
- Resistance$436.27+9.50%3 touches, last on October 9, 2026
- Resistance$416.30+4.49%2 touches, last on May 18, 2026
- Last price$398.40
- Support$392.37−1.51%6 touches, last on November 3, 2026
Volatility and risk
Over the last year it has moved roughly in line with the Hang Seng.
- Beta (1 year) vs Hang Seng
- 0.96
- Volatility (60 sessions, annualised)
- 47.9%
- Largest fall in the last year
- −28.83%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Sichuan Kelun-Biotech Biopharmaceutical and its competitors
With 2,300 employees, Sichuan Kelun-Biotech develops, manufactures and sells novel medicines for oncology, immunology and metabolic conditions, serving patients in China and in overseas markets. Its pipeline rests largely on antibody-drug conjugates, among them Sac-TMT, a TROP2-directed candidate that can be used alone or alongside other treatments for advanced solid tumors, and trastuzumab botidotin for HER2-positive tumors. Further candidates include a CLDN18.2 conjugate, a Nectin-4 conjugate, the PD-L1 antibody tagitanlimab and the RET inhibitor A400.
- Headquarters
- Chengdu, China
- Employees
- 2,300
- Founded
- 2016
- Chief executive
- Junyou Ge
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $12.15B | -0.2% | — | −8.83% |
| Sino Biopharmaceutical1177 | $11.65B | 28.2% | 34.2 | −1.26% |
| Pharmaron Beijing300759 | $10.59B | 14.0% | 39.3 | +44.36% |
| Innovent Biologics1801 | $17.82B | 7.4% | 105.4 | +0.88% |
| ALTEOGEN196170 | $9.05B | 47.2% | 97.1 | −36.93% |
| Haisco Pharmaceutical Group002653 | $8.97B | 21.1% | 44.1 | +0.54% |
Same industry or related industries, similar size. Compare Sichuan Kelun-Biotech Biopharmaceutical with its competitors · Full profile
More on Sichuan Kelun-Biotech Biopharmaceutical
- Sichuan Kelun-Biotech Biopharmaceutical revenue and financials
- Sichuan Kelun-Biotech Biopharmaceutical valuation
- Sichuan Kelun-Biotech Biopharmaceutical stock return
- Sichuan Kelun-Biotech Biopharmaceutical employees, headquarters and business
